Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
Discontinued
Reference number: GID-TA10416
The National Institute for Health and Care Excellence (NICE) has been asked to consider an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. The consultation on the draft scope closed on Friday 01 May 2020.
Following the receipt of an update from the company that market Ivosidenib, NICE has agreed that continuing the scoping exercise at this time would not be appropriate. As a consequence of this, the scoping exercise will not continue at this time and will be rearranged for a later date. We apologise for any inconvenience this may cause.
If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on (44 (0)161 413 4070 or via email on emily.richards@nice.org.uk)